151751-Najiba-Chargi

253 Systemic therapy: skeletal muscle mass and anti-cancer drug toxicity 29. Mazzuca F, Onesti CE, Roberto M, et al. Lean body mass wasting and toxicity in early breast cancer patients receiving anthracy- clines. Oncotarget . 2018;9(39):25714-25722. doi:10.18632/oncotarget.25394 30. Palmela C, Velho S, Agostinho L, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally ad- vanced gastric cancer. J Gastric Cancer . 2017;17(1):74-87. doi:10.5230/jgc.2017.17.e8 31. Panje CM, Höng L, Hayoz S, et al. Skeletal muscle mass correlates with increased tox- icity during neoadjuvant radiochemothera- py in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol . 2019;14(1). doi:10.1186/s13014-019-1372-3 32. Parsons HA, Tsimberidou AM, Pontikos M, et al. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemothera- py. Nutr Cancer . 2012;64(2):206-217. doi:10. 1080/01635581.2012.638433 33. Sawada K, Saitho Y, Hayashi H, et al. Skele - tal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with he- patocellular carcinoma receiving sorafenib treatment. JGH Open . 2019;3(4):329-337. doi:10.1002/jgh3.12167 34. Sealy MJ, Dechaphunkul T, Van Der Schans CP, et al. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. 2019. doi:10.1016/j. clnu.2019.02.029 35. Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemothera- py. Clin Cancer Res . 2017;23(3):658-665. doi:10.1158/1078-0432.CCR-16-0940 36. Shachar SS, Deal AM, Weinberg M, et al. Body Composition as a Predictor of Tox- icity in Patients Receiving Anthracycline and Taxane–Based Chemotherapy for Early-Stage Breast Cancer. Clin Cancer Res . 2017;23(14):3537-3543. doi:10.1158/1078- 0432.CCR-16-2266 37. Srdic D, Plestina S, Sverko-Peternac A, Ni- kolac N, Simundic A-M, Samarzija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non- small cell lung cancer—chemotherapy tox- icity and prognostic value. Support Care Cancer . 2016;24(11):4495-4502. doi:10.1007/ s00520-016-3287-y 38. Staley SA, Tucker K, Newton M, et al. Sar - copenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol . 2020;156(3):695-700. doi:10.1016/j. ygyno.2020.01.003 39. Sugiyama K, Narita Y, Mitani S, et al. Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer. Anticancer Res . 2018;38(10):5859-5866. doi:10.21873/anticanres.12928 40. Ueno A, Yamaguchi K, Sudo M, Imai S. Sar - copenia as a risk factor of severe laborato- ry adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. Support Care Cancer . 2020;28(9):4249-4254. doi:10.1007/ s00520-019-05279-x 41. Anandavadivelan P, Brismar TB, Nilsson M, Johar AM, Martin L. Sarcopenic obesi - ty: A probable risk factor for dose limiting toxicity during neo-adjuvant chemother- apy in oesophageal cancer patients. Clin Nutr . 2016;35(3):724-730. doi:10.1016/j. clnu.2015.05.011 13